The widening conflict in West Asia is emerging as a significant cost pressure for Indian pharmaceutical companies, with Dr Reddy's Laboratories reporting that the impact shaved about one percentage point off its first-quarter EBITDA margin. According to reports from Moneycontrol, CFO M V Narasimham attributed the margin compression to higher freight rates and solvent costs linked to the Middle East conflict. The company's Q1FY27 EBITDA margins stood at 12.5 percent, representing a significant drop compared to the year-ago period. Cipla is facing similar pressures with CFO Ashish Adukia noting that gross margins were impacted by 'certain war-related costs' and EBITDA margins at 16.7 percent for the quarter.
As reported by Moneycontrol, the conflict has created dual cost pressures across the pharmaceutical supply chain. Elevated freight costs pushed up selling and administrative expenses, while higher solvent costs weighed on gross margins. Solvents are critical ingredients in drug manufacturing, used in the synthesis, extraction and purification of active pharmaceutical ingredients. The cost increases are filtering through global shipping routes and petrochemical supply chains into pharmaceutical balance sheets as supply chains tighten and transportation becomes more expensive. Cipla's CEO Achin Gupta admits geopolitical tensions are making operations tougher, with even a weaker rupee failing to provide much relief since import prices continue climbing.
According to Moneycontrol reports, Cipla is facing similar pressures with CFO Ashish Adukia noting that gross margins were impacted by 'certain war-related costs'. CEO Achin Gupta described the operating environment as marked by 'certain external challenges mostly on the geopolitical front'. Both companies recorded significant drops in profitability compared to the year-ago period, with Cipla's EBITDA margins at 16.7 percent for the quarter. The problem is particularly acute for generic drugmakers whose products are sold under fixed contracts with distributors, hospitals and government agencies, making it difficult to pass on higher logistics or input costs.
As reported by Moneycontrol, CFO M V Narasimham highlighted the industry's weak ability to recover higher costs from buyers. 'Especially in the generics business, it is driven by contracts,' Narasimham explained, noting that price increases for solvents and logistics costs cannot be passed on to customers. The same limitation extends to the active pharmaceutical ingredients (API) business, with the company unable to see significant price increases with API customers. A weaker rupee has provided some relief by boosting export revenues, but this benefit is partly offset because imported solvents and raw materials are also paid for in foreign currency.
Despite acknowledging the cost pressures as manageable, both companies indicate that the impact could persist for some time. According to Moneycontrol reports, management from both Dr Reddy's and Cipla suggest these cost pressures could remain in the operating environment. The episode underscores how geopolitical tensions far from India can ripple through global supply chains and weigh on pharmaceutical earnings, creating new margin headwinds for the sector. Management warns this squeeze could persist for some time, as generic drugmakers struggle with fixed contract pricing structures that limit their ability to recover higher input costs.
